Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
1999-07-28
2001-10-23
Mosher, Mary E. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C424S202100, C424S816000, C435S320100, C435S235100
Reexamination Certificate
active
06306400
ABSTRACT:
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
Not applicable.
FIELD OF THE INVENTION
The present invention relates to vaccines for avian use based on infectious laryngotracheitis virus (ILTV) into which there has been inserted, by genetic recombination, at least one heterologous nucleotide sequence in particular encoding and expressing an antigenic polypeptide from an avian pathogenic agent, under conditions ensuring immunization leading to effective protection of the vaccinated animal against the said pathogenic agent.
BACKGROUND OF THE INVENTION
The infectious laryngotracheitis virus (ILTV) is an alphaherpesvirus (B. Roizman,
Arch. Virol.
1992. 123. 425-449) which causes a major respiratory pathology (infectious laryngotracheitis or ILT) in chicken (L. E. Hanson and T. J. Bagust,
Diseases of Poultry
9th edn 1991. pp 485-495. Ames, Iowa State University Press). The vaccines currently available against this condition contain an attenuated strain which can be administered by various routes including the intranasal, conjunctival and cloacal routes, in drinking water and by aerosol (L. E. Hanson and T. J. Bagust (1991).
Studies of the molecular biology of the ILTV virus have made it possible to characterize the viral genome (M. A. Johnson et al.,
Arch. Virol.
1991. 119. 181-198) and to identify some of the virus genes (A. M. Griffin,
J. Gen. Virol.
1989. 70. 3085-3089) including the genes encoding thymidine kinase (UL23) (A. M. Griffin and M. E. G. Boursnell,
J. Gen. Virol.
1990. 71. 841-850; C. L. Keeler et al.,
Avian Dis.
1991. 35. 920-929), the glycoprotein gB (UL27) (A. M. Griffin,
J. Gen. Virol.
1991. 72. 393-398; K. Kongsuwan et al.,
Virology
1991. 184. 404-410; D. J. Poulsen et al.,
Virus Genes
1991. 5. 335-347), the glycoprotein gC (UL44) (D. H. Kingsley et al.,
Virology
1994. 203. 336-343), the capsid protein p40 (UL26) (A. M. Griffin,
Nucl. Acids Res.
1990. 18. 3664), the protein homologous to the ICP4 protein of herpes simplex (HSV-1) (M. A. Johnson et al.,
Virus Research
1995. 35. 193-204), the proteins homologous to the proteins ICP27 (UL54), glycoprotein gK (UL53) and DNA helicase (UL52) from HSV-1 (M. A. Johnson et al.,
Arch. Virol.
1995. 140. 623-634), ribonucleotide reductase (A. M. Griffin, (1989); and WO-A-90/02802), the UL1 to UL5 genes (W. Fuchs and T. C. Mettentleiter,
J. Gen. Virol.
1996. 77. 2221-2229), the genes present in the short unique sequence of the genome (U
s
) (M. A. Johnson et al.,
DNA Sequence—The Journal of Sequencing and Mapping
1995. Vol. 5. pp 191-194; K. Kongsuwan et al.,
Arch. Virol.
1995. 140. 27-39; K. Kongsuwan et al.,
Virus Research
1993. 29. 125-140; K. Kongsuwan et al.,
Virus Gene
1993. 7. 297-303; M. A. Wild et al.,
Virus Genes
1996. 12. 107-116; WO-A-92/03554; and WO-A-95/08622).
BRIEF SUMMARY OF THE INVENTION
The aim of the present invention is to develop an avian vaccine based on recombinant ILTV virus expressing a heterologous gene, this virus being capable of replicating and inducing immunity in the vaccinated host while preserving good safety.
Another aim of the invention is to provide such a vaccine which is at the same time particularly effective against ILT.
Another aim of the invention is to provide such a vaccine which can be used in mass vaccination by the mucosal route, for example by the aerosol route or in drinking water, such that the replication of the virus at the mucosal level makes it possible to induce mucosal and systemic immunity. Such a mucosal immunity will be particularly effective for combating respiratory diseases as well as other diseases for which the route of entry of the pathogenic agent is mucosal.
Another aim of the invention is to provide such a vaccine which can be used both in adults and in young animals.
A specific aim is to provide such a vaccine which can be used in mass vaccination, by the mucosal route, of any young animals such as one-day old chicks.
Another aim of the invention is to provide a vaccine against ILT which has an increased efficacy compared with the parental strain and which may even possibly allow the insertion and expression of a heterologous gene.
REFERENCES:
patent: 6045803 (2000-04-01), Audonnet et al.
patent: 0 719 864 A2 (1996-07-01), None
patent: WO 92/03554 (1992-03-01), None
patent: WO 96/00791 (1996-01-01), None
Johnson et al (Arch. Virol. 140:623-634), 1995.*
Ren et al (Virology 204:242-250), 1994.
Audonnet Jean-Christophe
Bublot Michel
Laplace Eliane
Frommer William S.
Frommer & Lawrence & Haug LLP
Kowalski Thomas J.
Merial
Mosher Mary E.
LandOfFree
Avian recombinant live vaccine using, as vector, the avian... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Avian recombinant live vaccine using, as vector, the avian..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Avian recombinant live vaccine using, as vector, the avian... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2561648